Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note published on Friday, Benzinga reports. HC Wainwright currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently commented on the company. Piper Sandler raised their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an overweight rating in a report on Wednesday, March 20th. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an overweight rating in a research report on Friday, March 22nd. Barclays decreased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating on the stock in a research report on Friday. Royal Bank of Canada reaffirmed an outperform rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Finally, Needham & Company LLC reissued a buy rating and set a $222.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $192.75.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $0.72 on Friday, hitting $110.01. The company had a trading volume of 693,769 shares, compared to its average volume of 597,957. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of 22.68, a P/E/G ratio of 1.51 and a beta of 0.63. The company has a current ratio of 2.27, a quick ratio of 1.85 and a debt-to-equity ratio of 1.38. The stock’s 50-day simple moving average is $116.44 and its 200 day simple moving average is $121.10. Jazz Pharmaceuticals has a 12-month low of $103.01 and a 12-month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, equities research analysts expect that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Commerce Bank lifted its position in shares of Jazz Pharmaceuticals by 8.9% in the first quarter. Commerce Bank now owns 60,032 shares of the specialty pharmaceutical company’s stock valued at $7,229,000 after acquiring an additional 4,894 shares in the last quarter. Financial Counselors Inc. lifted its holdings in Jazz Pharmaceuticals by 28.2% in the 1st quarter. Financial Counselors Inc. now owns 2,376 shares of the specialty pharmaceutical company’s stock valued at $286,000 after purchasing an additional 522 shares in the last quarter. Wright Investors Service Inc. purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at $442,000. Daiwa Securities Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 18.7% during the first quarter. Daiwa Securities Group Inc. now owns 5,586 shares of the specialty pharmaceutical company’s stock worth $673,000 after buying an additional 879 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Jazz Pharmaceuticals by 45.1% in the first quarter. Janney Montgomery Scott LLC now owns 15,888 shares of the specialty pharmaceutical company’s stock valued at $1,913,000 after buying an additional 4,939 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.